The NMPA has accepted a supplemental application for subcutaneous toripalimab plus disitamab vedotin in first-line HER2-expressing urothelial carcinoma, following the May 2026 approval of the intravenous combination.
Related to this article
Adding durvalumab and enfortumab vedotin around cystectomy extended survival in muscle-invasive bladder cancer without cisplatin options.
Adding durvalumab to BCG induction and maintenance reduced high-risk recurrences in patients with papillary-only bladder tumors in POTOMAC.
Perioperative enfortumab vedotin plus pembrolizumab showed no clinically meaningful HRQOL detriment in cisplatin-eligible MIBC.
Advertisement
Advertisement
Trending on OncLive
1
Early Cancer Detection and Translational Biology Are Set to Shape the Future of Oncology
2
Tocilizumab Prophylaxis, Caregiver Readiness, and Chair Time Shape Community Bispecific Programs in R/R Myeloma
3
Treatment Selection and Biomarker Testing at Platinum Resistance
4
How Biomarkers Now Drive First-Line Therapy in mHSPC
5